PT928291E - 3-MERCAPTOACETILAMAMINE-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS - Google Patents

3-MERCAPTOACETILAMAMINE-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS

Info

Publication number
PT928291E
PT928291E PT97935308T PT97935308T PT928291E PT 928291 E PT928291 E PT 928291E PT 97935308 T PT97935308 T PT 97935308T PT 97935308 T PT97935308 T PT 97935308T PT 928291 E PT928291 E PT 928291E
Authority
PT
Portugal
Prior art keywords
mercaptoacetilamamine
oxo
substituted
matrix metaloproteinase
metaloproteinase inhibitors
Prior art date
Application number
PT97935308T
Other languages
Portuguese (pt)
Inventor
Michael J Janusz
Joseph Burkhart
Jiu-Tsair Tsay
Jian Shen
Ramalinga M Dharanipragada
Alan M Warshawsky
Gary A Flynn
Meena V Patel
Douglas W Beight
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PT928291E publication Critical patent/PT928291E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97935308T 1996-09-19 1997-08-04 3-MERCAPTOACETILAMAMINE-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS PT928291E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19

Publications (1)

Publication Number Publication Date
PT928291E true PT928291E (en) 2003-03-31

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97935308T PT928291E (en) 1996-09-19 1997-08-04 3-MERCAPTOACETILAMAMINE-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS

Country Status (21)

Country Link
EP (1) EP0928291B1 (en)
JP (1) JP3962091B2 (en)
KR (1) KR100545460B1 (en)
CN (1) CN1150205C (en)
AR (1) AR009363A1 (en)
AT (1) ATE229034T1 (en)
AU (1) AU718055B2 (en)
BR (1) BR9713207A (en)
CA (1) CA2266759C (en)
DE (1) DE69717647T2 (en)
DK (1) DK0928291T3 (en)
ES (1) ES2184126T3 (en)
HK (1) HK1020741A1 (en)
HU (1) HUP9904165A3 (en)
IL (2) IL129035A0 (en)
NO (1) NO991316L (en)
NZ (1) NZ334490A (en)
PT (1) PT928291E (en)
TW (1) TW445262B (en)
WO (1) WO1998012211A1 (en)
ZA (1) ZA978307B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
WO2000040553A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CN1416346A (en) 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 Peotease inhibitors
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
EP3630969B1 (en) 2017-05-31 2023-06-07 BRAIN Biotech AG Optimization of the expression of serine proteases in host cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2586942B2 (en) * 1987-03-17 1997-03-05 リサーチ コーポレーシヨン テクノロジーズ インコーポレーテツド Inhibitors of mammalian collagenase synthesis
JPH07304746A (en) * 1994-05-11 1995-11-21 Kanebo Ltd New benzoazepinecarboxylic acid derivative
WO1996011209A1 (en) * 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
IL129035A (en) 2006-12-10
JP2001501926A (en) 2001-02-13
DE69717647T2 (en) 2003-09-25
EP0928291B1 (en) 2002-12-04
JP3962091B2 (en) 2007-08-22
ZA978307B (en) 1998-03-19
HK1020741A1 (en) 2000-05-19
CA2266759C (en) 2004-10-26
CA2266759A1 (en) 1998-03-26
AU3827897A (en) 1998-04-14
DK0928291T3 (en) 2003-03-17
TW445262B (en) 2001-07-11
ATE229034T1 (en) 2002-12-15
CN1150205C (en) 2004-05-19
NO991316D0 (en) 1999-03-18
WO1998012211A1 (en) 1998-03-26
AU718055B2 (en) 2000-04-06
AR009363A1 (en) 2000-04-12
KR100545460B1 (en) 2006-01-24
HUP9904165A2 (en) 2000-03-28
BR9713207A (en) 2000-04-04
EP0928291A1 (en) 1999-07-14
HUP9904165A3 (en) 2002-01-28
NZ334490A (en) 2000-08-25
KR20000036246A (en) 2000-06-26
ES2184126T3 (en) 2003-04-01
NO991316L (en) 1999-05-18
DE69717647D1 (en) 2003-01-16
IL129035A0 (en) 2000-02-17
CN1234039A (en) 1999-11-03

Similar Documents

Publication Publication Date Title
PT946512E (en) 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES AS US INHIBITORS
CU23063A3 (en) IMIDAZOTRIAZINONES 2-PHENYL REPLACED AS PHOSPHODESTERASE INHIBITORS
PT1185529E (en) PYRAZOLOBENZODIAZEPINAS AS CDK2 INHIBITORS
PT818448E (en) CICLOALCANO-PYRIDINES AS CETP INHIBITORS
CU23082A3 (en) 4-CARBOXIAMINO-2-SUBSITUIDOS-1,2,3,4- TETRAHYDROQUINOLAS AS CETP INHIBITORS
PT1140840E (en) DIFENILUREIAS SUBSTITUTED WITH (.) - CARBOXYARILLUS AS RAF-KINASE INHIBITORS
PT901474E (en) ARIL-PYRIMIDINE DERIVATIVES.
NL1016815A1 (en) Oximester photoinitiators.
NO983764D0 (en) Jack, especially for carry channels
DE69725473D1 (en) THIN, ABSORBENT OBJECT
IT1306971B1 (en) HYDRAULIC DISTRIBUTOR.
NO995967D0 (en) Softener-treated absorbent interlabial object
PT942901E (en) CYCLICAL IMPLICATIONS USED AS PESTICIDES
PT928291E (en) 3-MERCAPTOACETILAMAMINE-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS
PT858452E (en) TIAZOL DERIVATIVES AS A PROTEIN KINASE C INHIBITOR
PT1147095E (en) ACIDS 2,3,4,5-TETRA-1H- [1,4] BENZODIAZEPINO-3-HYDROXAMICS AS MATRIX METALOPROTEINES INHIBITORS
ID22228A (en) 16-HYDROXY-11- (DISUBSTITUSIFENIL) -ESTRA-4,9-DIENA
PT1100792E (en) TRICYCLIC SULFONAMID AND ITS DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS
PT922050E (en) 3-DESCLADINOSE-2,3-ANYDROERITROMYCIN DERIVATIVES
PT1189907E (en) TIENOPYRIMIDINES AS PHOSPHODIESTERASE INHIBITORS
PT1047665E (en) MATRIX METALOPROTEASE INHIBITORS
PT1153015E (en) PYRIMIDINE-2,4,6-TRIOES UTEIS AS INHIBITORS OF MATRIX METALOPROTEINASES
BR9706239B1 (en) 3- (1-hydroxyphenyl-1-alkoxyiminomethyl) dioxazins as well as processes for preparing same.
PT1121349E (en) TIADIAZOLSULFONAMIDES REPLACED AS INTERLEUCIN-1-BETA INHIBITORS
PT920330E (en) HCG AND DERIVATIVES AS MATRIX METALOPROTEASE INHIBITORS